Emergent BioSolutions anthrax vaccine gets boost - Los Angeles Business from bizjournals:

burwellmitubaes1369.blogspot.com
The Rockville-based company’s BioThrax has been granted a shelfv life extension from the from its current three yearesto four. Under its contract with the Departmengt of Health and Human the extension triggers a milestone paymentof $30 milliomn for doses of the vaccine already deliveredc to the Strategic Nationaol Stockpile. Emergent expects to record that payment as revenurethis quarter. The shelf life extensiohn also allows Emergent to charge more for future dose of the vaccine delivered tothe government’s That could raise the value of the contracf to as much as $405 million over the next several years. Last year, the FDA approvex a reduced vaccination schedule tofive doses.
Emergent continues researcn that could lead to a furthe reduction in the number ofdoses required, as well as the vaccine’ use to treat patients afte being exposed to Anthrax, not just as a pre-exposuree vaccine. Emergent has supplied the government’s stockpiled with 33 million doses of BioThra xso far. It is contracted to continus adding to stockpiles throughlate 2011. BioThrax has been used to vaccinatde more than 2 million military personnel sincer the government first started buying the vaccinsein 1998. Emergent stock EBS) was up 90 cents to $14.63 per sharwe in afternoon trading.